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Background and Objective
Vitamin K epoxide reductase complex, subunit 1 (VKORC1) and cytochrome P450
2C9 (CYP2C9) polymorphisms are taken into account when predicting a safe oral
dose of coumarin anticoagulant therapy, but little is known about the effects of
genetic predictors on the response to fluindione and acenocoumarol. The aims of
this study were to characterize the relationship between fluindione and
acenocoumarol concentrations and the international normalized ratio (INR)
response, and to identify genetic predictors that are important for dose
individualization.
Methods
Fluindione concentrations, S- and R-acenocoumarol concentrations, the INR and
genotype data from healthy subjects were used to develop a population
pharmacokinetic-pharmacodynamic model in Monolix software. Twenty-four White
healthy subjects were enrolled in the pharmacogenetic study. The study was an
open-label, randomized, two-period cross-over study. The subjects received two
doses of an oral anticoagulant: 20 mg of fluindione (period A) or 4 mg of
acenocoumarol (period B). The pharmacokinetics and pharmacodynamics were
studied from day 2 to day 3.
Results
A two-compartment model with a first-order input model was selected as the base
model for the two drugs. The pharmacodynamic response was best described by an
indirect action model with S-acenocoumarol concentrations and fluindione
concentrations as the only exposure predictors of the INR response. Three
covariates (CYP2C9 genotype, VKORC1 genotype and body weight) were identified
as important predictors for the pharmacokinetic-pharmacodynamic model of S-
acenocoumarol, and four covariates (CYP2C9 genotype, VKORC1 genotype,
CYP1A2 phenotype and body weight) were identified as predictors for the
pharmacokinetic-pharmacodynamic model of fluindione. Because some previous
studies have shown a dose-response relationship between smoking exposure and
the CYP1A2 phenotype, it was also noted that smokers have greater CYP1A2
activity.
Conclusion
During initiation of therapy, CYP2C9 and VKORC1 genetic polymorphisms are
important predictors of fluindione and acenocoumarol pharmacokinetic-
pharmacodynamic responses. Our result suggests that it is important to take the
CYP1A2 phenotype into account to improve individualization of fluindione therapy,
in addition to genetic factors.
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